Disseminated intravascular coagulation (DIC) is a severe complication of sepsis, especially when associated with skin or organ necrosis appearing as purpura fulminans. Several reports described beneficial effects of protein C replacement in preterm neonates, infants, and adults with purpura fulminans. We treated seven adult patients (six female, one male), median age 35 years (range 19--48 years), with DIC and purpura fulminans with a plasma-derived human protein C concentrate (Ceprotin^®^; Baxter, Vienna, Austria). Three patients had meningococcal, three had pneumococcal, and one had pseudomonas and cytomegaly-virus infections. At admission, all patients had signs of skin necrosis, severe infection and acute illness. Coagulation assays suggested DIC in five patients (median \[range\]): platelet count 19 (17--23) G/l, fibrinogen 60 (44--103) mg/dl, antithrombin activity 0.47 (0.25--0.76) U/ml, normotest 32 (14--39)%, APTT 88 (42--160) s, D-dimer 66 (3.3--140) ng/ml; the remaining two patients were treated because of typical skin necrosis and meningococcemia alone. Initial protein C activity was reduced to 0.35 (0.2--0.5) U/ml. Five patients had neurologic alterations, five renal failure, three respiratory failure, one a large intrahepatic necrosis. In five patients Ceprotin^®^ was given as a level-adjusted continuous infusion (starting with 10 U/kg per hour) after an initial bolus of 100 U/kg, two patients were treated with bolus infusions (100 U/kg every 8 hours). Additionally, heparin infusions (seven patients), fresh-frozen plasma (five patients), antithrombin concentrates (three patients), fibrinogen concentrates (two patients), low-dose rtPA (two patients), platelet and erythrocyte transfusions, antibiotics, and hydrocortisone (four patients) were given. Protein C activity increased to 1.34--2.0 U/ml in all patients, coagulation abnormalities resolved within 1--6 days. A total of 8000--77,000 U Ceprotin^®^ were given during 1--7 days. One patient died the same day from multiorgan failure, one died 14 days after the end of Ceprotin^®^ infusion from candida sepsis. All other patients survived, three needed amputations of toes, two had no sequels. Our data suggest that Ceprotin^®^ can be a useful hemostatic support in the treatment of adults with severe, life-threatening purpura fulminans, which would have a high mortality with conventional therapy alone. Controlled studies are needed to establish the value of this drug in the treatment of sepsis.
